LAGARRIGUE acquired by AZULIS CAPITAL, BNP PARIBAS DEVELOPPEMENT & GALIA
Context
Following an initial OBO three years prior (where debt was fully repaid), Lagarrigue completed a majority LBO led by Azulis Capital. The consortium, including BNP Paribas Developpement, Galia Gestion, and historical investor iXO PE, acquired approximately 80% of the capital. The operation marked the full exit of the founder, who sold his remaining 20% stake. The manager and key executives reinvested for the remaining 20%. The deal was structured conservatively with 70% Equity/Mezzanine and only 30% Senior Debt to allow headroom for acquisitions in a fragmented market.
LAGARRIGUE, which reported an EBITDA margin of [members only] in 2010, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Based in Toulouse, Lagarrigue is a leading French provider of external orthopaedic devices (prosthetics and orthotics). The group specializes in custom-made solutions (95% of activity) for patients with disabilities. Under previous ownership, it tripled its size, expanding into Switzerland, Belgium, and Spain, and digitized its operations through software subsidiaries (Rodin 4D, Vorum).
Ent. Value
€10–30M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with LAGARRIGUE
Other operations with LAGARRIGUE
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2021 | NAXICAP PARTNERS | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 09/2016 | ARDIAN / IXO PRIVATE EQUITY | LAGARRIGUE | FRANCE | Implants & Prosthetics |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
| 08/2012 | BC PARTNERS | AENOVA GROUP | GERMANY | CDMO |
| 09/2010 | SPARRING CAPITAL | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 04/2007 | ASTORG | ETHYPHARM | FRANCE | Pharma & Biotech |
| 01/2006 | EDMOND DE ROTHSCHILD CAPITAL PARTNERS | ACTEON | FRANCE | Medical Devices |
Other operations with AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2026 | AZULIS CAPITAL | Ceetadel | FRANCE | Digital Marketing, SEO, SEA, Data Analytics |
| 04/2026 | AZULIS CAPITAL | MEWS PARTNERS | FRANCE | Strategy & Management |
| 05/2025 | AZULIS CAPITAL | ACENSI | FRANCE | Consulting & Integration |
| 01/2020 | AZULIS CAPITAL | TALIS EDUCATION GROUP | FRANCE | Education Providers |
| 07/2016 | AZULIS CAPITAL | LA BOUTIQUE OFFICIELLE.COM | FRANCE | E-commerce & Marketplaces |
| 09/2014 | AZULIS CAPITAL | ITAL EXPRESS | FRANCE | B2B Specialized Distribution |
| 09/2012 | AZULIS CAPITAL | HOLWEG WEBER | UNITED STATES | Robotics & Automation |
REFERENCES
Revenue range: €10–30M
EBITDA range: €0–5M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LAGARRIGUE by AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: lagarrigue
Acquirer: azulis capital / bnp paribas developpement / galia